MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access

MaxCyte, Inc. (MXCT) has disclosed a new risk, in the Share Price & Shareholder Rights category.

MaxCyte, Inc. faces a material risk that it may fail to regain or maintain compliance with Nasdaq’s minimum bid price and other listing standards, following notice that its shares traded below $1.00 for an extended period. An eventual delisting could severely impair liquidity, depress the trading volume and market price of its common stock, and constrain access to capital.

If MaxCyte’s stock were moved to an over-the-counter market or reclassified as a penny stock, investors would likely encounter wider spreads, lower analyst coverage, and more onerous trading rules. Such outcomes could reduce market confidence among shareholders, customers, suppliers, and employees, ultimately weighing on the company’s business prospects and financing flexibility.

The average MXCT stock price target is $5.00, implying 597.54% upside potential.

To learn more about MaxCyte, Inc.’s risk factors, click here.